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COVID-19 is caused by a novel single-stranded RNA virus (SARS-
CoV-2) that was initially identified in Wuhan, China, in December 
2019.[1,2] The continuing global spread of the SARS-CoV-2 coronavirus 
is of particular concern for pregnant and lactating women, because they 
are at an increased risk of complications if they become infected by 
the virus. In pregnancy, the infection can result in complications such 
as stillbirths and preterm delivery, and increases in caesarean delivery 
rates (both iatrogenic and spontaneous), perinatal loss and even 
maternal death when compared with non-infected pregnant women.[3,4]
SARS-CoV-2 commonly spreads from person to person via 
respiratory droplets/nasal discharge. The current measures to prevent 
the spread of the COVID-19 pandemic are therefore use of public 
health guidelines such as physical distancing in public spaces, not 
congregating in large crowds, the wearing of facial coverings such 
as masks/shields, and the frequent washing of hands with soap and 
water. In the absence of the latter, the frequent use of alcohol-based 
sanitisers is recommended.[1,2] The global health crisis created by 
the pandemic necessitates a co-ordinated public health response 
that also includes effective and strategic roll-out of vaccinations 
to the population to gain control of viral spread and achieve herd/
population immunity.[1-5]
The abovementioned public health measures have been reported 
to be effective in limiting the spread of the disease.[6] Although such 
measures are effective, they are dependent on individual and societal 
behaviour and may be difficult to maintain in all population groups 
over a long period of time.[6] This is crucial because the fear and 
anxiety created by the lockdown/restriction measures that restrict 
socioeconomic activities have led to a worldwide increase in mental 
health issues and gender-based violence, including in South Africa 
(SA).[7] Saccone et al.[8] reported that among pregnant women, more 
than half of the respondents rated the psychological impact of the 
COVID-19 outbreak as severe, and two-thirds reported higher-than-
normal anxiety levels.
While there has been some success in addressing the pandemic 
through societal mechanisms, no pharmaceutical drugs have yet 
been proven effective for the prevention or treatment of mild to 
moderate COVID-19 disease. There are some agents, however, 
such as dexamethazone and remdesivir, an antiretroviral drug used 
for the management of Ebola, that have been used successfully,[9-11] 
notably in shortening the duration of hospital stay for patients who 
develop severe COVID-19 disease.[9,10] Currently, there is no drug 
generally accepted as preventive therapy for COVID-19 infection. 
Implementation of widespread vaccination programmes may result 
in herd/population immunity and prevent rapid spread of the disease 
and serious complications, including mortality.[12,13] It is therefore 
not surprising that numerous human clinical trials are being carried 
out to prevent SARS-CoV-2 infection.[12,13] However, no randomised 
COVID-19 clinical trials (RCTs) or vaccine trials to date have 
included pregnant women.[13] Vaccination of pregnant women has, 
however, been recommended to prevent seasonal influenza, pertussis 
and tetanus.[14] Clinical data on the safety and efficacy of influenza 
immunisation have been provided by an RCT involving 3 693 
pregnant women in Nepal, in which immunisation was shown to 
decrease maternal influenza-like illness by 19% and infant influenza 
disease by 30%.[14] Given that COVID-19 is highly infectious and 
results in increased morbidity and mortality among pregnant women, 
we argue that pregnant and lactating individuals should be permitted 
and prioritised to receive the COVID-19 vaccine.[3,4,14]
Methods
A literature search was performed of all articles in the databases 
PubMed, Google Scholar and Clinical Keys using the keywords 
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In view of the continuing worldwide spread of COVID-19 infection, the increased morbidity and mortality from the disease during 
pregnancy, and the current efficacy and safety of vaccines in non-pregnant individuals, vaccines should not be withheld from women 
simply because of pregnancy or lactation. All pregnant women, especially healthcare professionals, should be offered vaccination and 
counselled about its advantages and disadvantages by their maternity care providers. Complete eradication of COVID-19 infection will be 
possible if potential niduses of the infection, which may act as sources for future outbreaks, are protected against the pathogen. However, if 
a hypothetical medication is the only means yet proven of limiting severe compromise to maternal health, access to the medication should 
be at the pregnant woman’s discretion. Shared decision-making requires physicians to actively engage with their patients and share their 
knowledge about the subject matter.
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COVID-19, COVID-19 vaccination, Pregnancy, and Maternal health. 
The information was accessed from 2020 to 2021, since roll-out of 
COVID-19 vaccination commenced in 2021 in SA.
COVID-19 vaccines
There are currently three types of COVID-19 vaccines, viz. mRNA 
vaccines, viral vector vaccines and protein subunit vaccines, which 
have been or are being developed and investigated in clinical trials 
worldwide.[5,12] None of these types of vaccines can cause COVID-
19, because they produce antigens that stimulate the body’s immune 
system, resulting in the production of T- and B-lymphocytes to guard 
against future infection.[5,12,13]
A considerable amount of data have been produced from some 
COVID-19 clinical trials (Pfizer BTN162b2, Moderna, AstraZeneca-
Oxford and Sputnik vaccines).[5] The data include information on 
efficacy and safety. In general, these vaccines are all effective and well 
tolerated, with no serious safety concerns.[5] Owing to the results of 
studies on these vaccines, some of them have received emergency 
authorisation for vaccination programmes, and countries such as the 
UK and the USA have initiated immunisation programmes.
Considering the data available, it is surprising that pregnant 
and lactating women were excluded from the vaccine trials.[5,14,15] 
Presumably their exclusion is based on theoretical risks of harm 
to the fetus and transmission of the virus to the baby during 
lactation. Pharmaceutical companies are concerned about litigation 
post vaccination. However, the vaccine is of particular importance 
because current data on the impact of COVID-19 on pregnancy 
show an increase in stillbirths, preterm births, and even mortality 
compared with non-pregnant women.[3,4] Furthermore, the American 
College of Obstetricians and Gynaecologists (ACOG) and the Society 
for Maternal-Fetal Medicine (SMFM) have advocated the inclusion 
of pregnant and breastfeeding women in vaccine trials.[16] There are 
also professional organisations that have indicated that healthcare 
workers, who are being considered as a priority group for vaccination, 
should be offered the vaccine if they are pregnant.[16,17] Furthermore, 
it is argued that in an active outbreak, pregnancy is associated with 
increased susceptibility to severe disease, and an effective approach to 
protecting the infant is through passive placental antibody transfer.[13]
Withholding globally approved vaccines from pregnant and 
breastfeeding women based on theoretical risks may be considered 
unethical, given the increased adverse events in pregnant women 
infected with SARS-CoV-2. Furthermore, vaccination of pregnant 
women against seasonal influenza, pertussis and tetanus is based 
on the increased risks that these infections pose to the pregnant 
woman and her fetus, and the well-established safety profiles for these 
inactivated vaccines.[13] Balancing the appropriateness of medical 
therapy and other treatments during pregnancy continues to 
be a challenging issue in ethics, especially when there appears 
to be a misalignment of maternal and fetal interests. However, 
most obstetric ethicists believe that it is the pregnant patient 
who is best placed to make choices regarding whether or not 
an intervention is appropriate for her. Maternal autonomy is of 
paramount importance, and it trumps the uncertainty presented by 
the paucity of safety data.[17,18]
Severity of COVID-19 infection in pregnancy
At present, there is controversy as to whether pregnant women 
should be included in vaccination programmes.[13-18] In SA, there is 
no clear indication that pregnant and lactating individuals would 
be included in the vaccination roll-out. We believe that a strong 
case can be made for inclusion of all pregnant women, or at least 
all pregnant health professionals regarded as being at increased risk 
of contracting COVID-19. International bodies such as the Royal 
College of Obstetricians and Gynaecologists recommend the vaccine 
for pregnant individuals who are at high risk of contracting the 
disease (e.g. healthcare workers) and those with comorbidities. The 
Food and Drug Administration and Centers for Disease Control and 
Prevention adopt a similar stance. Canada and Ireland argue that the 
risk/benefit ratio is in favour of vaccinating, and pregnant women 
should therefore benefit from the intervention.[2,16,19]
Current data, including a rapid appraisal of the impact of the first 
wave of COVID-19 on the use of maternal and reproductive health 
services and on perinatal deaths in SA, show an increase in maternal 
deaths since the lockdown started, compared with the same period in 
2019.[20] These deaths may have been due to COVID-19 rather than 
indirect effects of COVID-19 exerting undue pressure on limited 
resources available for maternal health services, and/or pregnant 
women not attending healthcare services timeously. Furthermore, 
this increase in maternal deaths in SA should be analysed in terms 
of a decade in which the maternal mortality ratio has been declining 
yearly from the peak in 2010 - 2011.[21] In addition, there was an 
increase in stillbirths and preterm labours.[20] This scenario indicates 
that pregnant women are a vulnerable group, and recent US data 
evaluating pregnant and non-pregnant women with laboratory-
confirmed SARS-CoV-2 also support this.[3,4] Physiological changes 
to the cardiorespiratory and immune systems in pregnancy increase 
maternal susceptibility to infection and hypoxia. One-fifth of healthy 
women in late pregnancy will suffer from gestational rhinitis caused 
by oestrogen-mediated hyperaemia of the nasopharynx, which may 
result in masking of the coryzal symptoms of COVID-19, allowing 
for unchecked transmission. Maternal pulmonary volumes are also 
decreased, and physiological dyspnoea needs to be distinguished 
from shortness of breath caused by COVID-19.[18]
Delahoy et al.[3] found that of 598 pregnant women found to be 
positive for COVID-19 when hospitalised for various reasons between 
March and August 2020, 326 (55%) did not have COVID symptoms at 
admission. Symptomatic women generally had severe disease, and 44 
of the severe cases required treatment in an intensive care unit (ICU). 
There were two deaths among these 598 women (1%). The authors 
point out that ~5% of women of childbearing age (15 - 49 years) in the 
general population are pregnant; in their study, 26.5% of hospitalised 
women with COVID-19 in this age group were pregnant, indicating that 
pregnant women may be more susceptible to severe illness, although 
this figure could be confounded by the lower admission threshold that 
healthcare providers have when faced with pregnant women.[3,4]
The study by Delahoy et al.[3] also found that an overall 7.4% of 
all pregnant COVID-19-positive patients were admitted to an ICU, 
which is on par with the European statistic of 7.8%. However, in the 
symptomatic cohort of pregnant patients, this number jumped to 
16.2%, implying that pregnant women with acute illness may have 
more severe outcomes.[3] Another study from the USA, published 
in November 2020, evaluated the characteristics of women of 
reproductive age who were symptomatic with laboratory-confirmed 
SARS-CoV-2 infection. It was found that among 400 000 women aged 
15 - 44 years with symptoms of COVID-19, ICU admission, invasive 
ventilation, extracorporeal oxygenation and death were more likely in 
pregnant women than in non-pregnant women (10.5 v. 3.9 per 1 000 
cases, adjusted relative risk 3.0).[4] Such data strongly suggest that 
pregnant women fall into the vulnerable group and are at increased 
risk of severe illness and death. They should therefore be counselled 
about the proven measures to prevent SARS-CoV-2 infection, 
and signs and symptoms for which to seek COVID-19 testing and 
treatment. There is consensus that receiving a recommendation for 
vaccination from a healthcare provider is the most important factor 
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in maternal decision-making, irrespective of geographical or social 
context. If an area of uncertainty exists, the final decision should 
be taken by the pregnant woman in consultation with healthcare 
providers who are knowledgeable about the risk/benefit ratio and the 
values and circumstances of the patient.[17]
COVID-19 vaccination in pregnancy 
and lactation
Now that SA is embarking on a COVID-19 vaccination programme, 
strong consideration should be given to vaccinating pregnant and 
lactating women and promoting their inclusion in future clinical 
vaccine studies, based on the following points:
• There is good evidence that pregnant women are among the 
vulnerable groups at increased risk of severe disease and that they 
are more likely to suffer increased COVID-19-related morbidity 
and mortality compared with non-pregnant women.
• Withholding globally approved vaccines from pregnant and 
breastfeeding women simply on the basis of theoretical risks may 
be considered unethical, given the increased adverse maternal and 
perinatal risks associated with COVID-19.
• It is standard practice to offer all pregnant women vaccination 
against seasonal influenza, pertussis and tetanus. Their use is 
based on the increased risk that these infections pose to the mother 
and the baby, and the well-established safety profiles for the 
inactivated vaccines. Vaccines are immunogenic, and individuals 
may experience body aches, fever and headaches for a few days. 
These side-effects are not life-threatening and must be recognised 
and discussed with the healthcare provider.
• Several professional organisations including the ACOG have 
consistently advocated for the inclusion of pregnant and lactating 
women in vaccine trials.
• The SMFM also strongly recommends that pregnant women should 
have access to COVID-19 vaccines. This recommendation includes 
pregnant healthcare professionals, who are considered a priority 
for vaccination. The South African Society of Obstetricians and 
Gynaecologists has released a ‘poster’ suggesting that all pregnant 
women at increased risk of COVID-19 (diabetics, and obese and 
hypertensive pregnant women) should be offered the vaccine.
• The fetal impact of COVID-19 vaccination is unknown, and the 
potential for fetal risk must be acknowledged. However, there have 
been animal studies that have shown no adverse effects on the 
embryo. Furthermore, during one vaccine trial, a small number of 
women were discovered to be pregnant; some of these pregnancies 
were ongoing at the time of writing this article, while there were no 
fetal/perinatal effects in those who had given birth.
Conclusions
Pregnant and lactating women should be considered in clinical trials 
during pandemics such as COVID-19. Several research investigations 
have shown that pregnant women are more susceptible to COVID-
19 than non-pregnant women. Furthermore, studies have reported 
an increased rate of preterm births and stillbirths in COVID-19 
pregnancies. We therefore highly recommend that pregnant women, 
especially those with comorbidities, are vaccinated, as COVID-19 
poses a risk not only to maternal health but to fetal viability as well.
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